Sumeru Pharma Profile
Key Indicators
- Authorised Capital ₹ 4.50 Cr
- Paid Up Capital ₹ 1.05 Cr
- Company Age 14 Year, 3 Months
- Last Filing with ROC 31 Mar 2015
- Open Charges ₹ 1.00 Cr
- Revenue Growth -3.60%
- Profit Growth 111.88%
- Ebitda -2.45%
- Net Worth 0.60%
- Total Assets 2.64%
About Sumeru Pharma
Sumeru Pharma Limited (SPL) is a Public Limited Indian Non-Government Company incorporated in India on 26 November 2010 and has a history of 14 years and three months. Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2015. It's a company limited by shares with an authorized capital of Rs 4.50 Cr and a paid-up capital of Rs 1.05 Cr.
The company currently has active open charges totaling ₹1.00 Cr.
Devineni Rao, Kuchipudi Rao, Devineni Padmaja, and Two other members serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24232TG2010PLC071400
- Company No.
071400
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
26 Nov 2010
- Date of AGM
30 Sep 2015
- Date of Balance Sheet
31 Mar 2015
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Sumeru Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Devineni Padmaja  | Managing Director | 26-Nov-2010 | Current |
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Devineni Rao | Director | 26-Nov-2010 | Current |
| Kuchipudi Rao | Director | 26-Nov-2010 | Current |
| Devineni Sahul | Director | 26-Nov-2010 | Current |
| Devineni Chowdary | Director | 15-Apr-2011 | Current |
Financial Performance of Sumeru Pharma.
Sumeru Pharma Limited, for the financial year ended 2015, experienced Minor drop in revenue, with a 3.6% decrease. The company also saw a substantial improvement in profitability, with a 111.88% increase in profit. The company's net worth moved up by a moderate rise of 0.6%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sumeru Pharma?
In 2015, Sumeru Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹1.00 Cr
₹0
Charges Breakdown by Lending Institutions
- Canara Bank : 1.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Mar 2012 | Canara Bank | ₹1.00 Cr | Open |
How Many Employees Work at Sumeru Pharma?
Unlock and access historical data on people associated with Sumeru Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sumeru Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sumeru Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.